Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade

Oculis Holding AG (NASDAQ:OCS)’s stock price gapped up before the market opened on Friday after Stifel Nicolaus raised their price target on the stock from $35.00 to $40.00. The stock had previously closed at $19.48, but opened at $20.75. Stifel Nicolaus currently has a buy rating on the stock. Oculis shares last traded at $20.7950, with a volume of 43,282 shares trading hands.

Other equities analysts have also issued research reports about the stock. Lifesci Capital assumed coverage on shares of Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and issued a $51.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Oculis in a report on Tuesday, November 11th. Finally, HC Wainwright raised their price objective on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Institutional Investors Weigh In On Oculis

A number of large investors have recently added to or reduced their stakes in OCS. Bosun Asset Management LLC bought a new stake in shares of Oculis in the second quarter worth $378,000. Marshall Wace LLP bought a new stake in Oculis during the 2nd quarter worth approximately $393,000. Geode Capital Management LLC lifted its holdings in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. Finally, Woodline Partners LP increased its stake in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Stock Up 8.0%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The company’s 50-day moving average price is $20.10 and its 200 day moving average price is $18.85. The stock has a market capitalization of $1.10 billion, a P/E ratio of -8.31 and a beta of 0.32.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. As a group, equities analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.